Agios Pharmaceuticals Inc (NASDAQ: AGIO) on Tuesday, plunged -3.28% from the previous trading day, before settling in for the closing price of $35.35. Within the past 52 weeks, AGIO’s price has moved between $20.96 and $62.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 2.66%. The company achieved an average annual earnings per share of 280.76%. With a float of $55.14 million, this company’s outstanding shares have now reached $57.02 million.
Let’s determine the extent of company efficiency that accounts for 383 employees. In terms of profitability, gross margin is 76.16%, operating margin of -1238.1%, and the pretax margin is 2212.98%.
Agios Pharmaceuticals Inc (AGIO) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Agios Pharmaceuticals Inc is 3.32%, while institutional ownership is 104.72%. The most recent insider transaction that took place on Dec 11 ’24, was worth 9,256. In this transaction Director of this company sold 200 shares at a rate of $46.28, taking the stock ownership to the 15,483 shares. Before that another transaction happened on Nov 08 ’24, when Company’s Principal Accounting Officer sold 772 for $56.09, making the entire transaction worth $43,301. This insider now owns 813 shares in total.
Agios Pharmaceuticals Inc (AGIO) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.7 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 280.76% per share during the next fiscal year.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Trading Performance Indicators
Agios Pharmaceuticals Inc (AGIO) is currently performing well based on its current performance indicators. A quick ratio of 8.77 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 59.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.37, a number that is poised to hit -1.69 in the next quarter and is forecasted to reach -6.13 in one year’s time.
Technical Analysis of Agios Pharmaceuticals Inc (AGIO)
Looking closely at Agios Pharmaceuticals Inc (NASDAQ: AGIO), its last 5-days average volume was 1.33 million, which is a jump from its year-to-date volume of 0.73 million. As of the previous 9 days, the stock’s Stochastic %D was 3.90%. Additionally, its Average True Range was 3.32.
During the past 100 days, Agios Pharmaceuticals Inc’s (AGIO) raw stochastic average was set at 1.36%, which indicates a significant increase from 1.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 118.96% in the past 14 days, which was higher than the 64.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $49.18, while its 200-day Moving Average is $42.20. However, in the short run, Agios Pharmaceuticals Inc’s stock first resistance to watch stands at $35.21. Second resistance stands at $36.24. The third major resistance level sits at $36.94. If the price goes on to break the first support level at $33.48, it is likely to go to the next support level at $32.78. Should the price break the second support level, the third support level stands at $31.75.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Key Stats
Market capitalization of the company is 1.95 billion based on 57,030K outstanding shares. Right now, sales total 26,820 K and income totals -352,090 K. The company made 8,960 K in profit during its latest quarter, and 947,920 K in sales during its previous quarter.
